Register
|
Login
The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
NEWS
CONFERENCES
VIDEOS
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
PUBLICATIONS
Evolving Paradigms
Targeted Therapies in Oncology
The Journal of Targeted Therapies in Cancer
ONCAlert | ESMO 2018 Congress
Specialties >>
Acute Myeloid Leukemia
Biosimilars
Bladder Cancer
Brain Cancer
Breast Cancer
Chronic Lymphocytic Leukemia
Colorectal Cancer
Follicular Lymphoma
Gastric Cancer
Gastrointestinal Cancers
Genitourinary Cancers
Gynecologic Cancers
Head and Neck Cancers
Hematology
Hepatocellular Carcinoma
Immunotherapy
Lung Cancer
Lymphomas
Mantle Cell Lymphoma
Melanoma
Multiple Myeloma
Myeloproliferative Neoplasms
Ovarian Cancer
Prostate Cancer
Renal Cell Carcinoma
Soft Tissue Sarcoma
Thyroid Cancers
Partners >>
Dialogues in Diagnostics
Differential Diagnosis
Case-Based Peer Perspectives
Email Sign-Up
Evolving Paradigms
2018
|
2017
|
2016
|
2015
Role of Immunotherapy in NSCLC
Mantle Cell Lymphoma
Chronic Lymphocytic Leukemia
Breast Cancer: Focus on CDK4&6 Inhibitors
Immunotherapy in Nonsquamous Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Soft Tissue Sarcoma
Clinical Advances in Prostate Cancer
Triple Negative Breast Cancer
Pancreatic Cancer
BRAF-Mutant Melanoma
CDK4&6 Inhibition
Sequencing Strategies in Prostate Cancer
Bladder Cancer
Lymphoma
Immuno-Oncology: Checkpoint Inhibitors
Squamous NSCLC
Gynecologic Cancer
JTT Articles
The Role of JAK2 Inhibition in Polycythemia Vera
Current and Emerging Immunotherapy Strategies in Advanced Urothelial Cancers
Small Cell Transformation: An Increasingly Common Mechanism of Resistance in EGFR-Mutated Lung Cancer
>> View Peer-Reviewed Articles
Most Popular
Apalutamide Granted FDA's Priority Review for Nonmetastatic CRPC
Clinical Implications for Inherited BRCA Mutations Are Explored in Ovarian Cancer
Talazoparib Receives FDA Approval in BRCA-Mutated, HER2-Negative Breast Cancer
Dr. Lonial Discusses the Importance of Partnering With a Myeloma Center
